CA
TDACW

Crossingbridge Advisors’s Translational Development Acquisition Corp Warrants TDACW Stock Holding History

Crossingbridge Advisors’s Portfolio TDACW Stock Details TDACW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-292,500
Closed -$257K – 113
2025
Q1 		$257K Buy
+292,500
New +$51.5K 0.14% 58

Other funds holding TDACW

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Crossingbridge Advisors's TDACW Position: Q2 2025 in Review

Crossingbridge Advisors sold out of Translational Development Acquisition Corp Warrants (TDACW) in Q2 2025, closing a stake of 292,500 shares — an estimated $257K sold.

Crossingbridge Advisors first reported a position in TDACW in Q1 2025 and held it in 1 quarter. The position peaked at $257K in Q1 2025. 28 funds tracked by Wall St. Rank hold TDACW as of Q2 2025.

  • Crossingbridge Advisors reported no remaining Translational Development Acquisition Corp Warrants position as of Q2 2025 after selling out during the quarter.
  • Crossingbridge Advisors sold 292,500 Translational Development Acquisition Corp Warrants shares in Q2 2025, an estimated $257K.
  • Crossingbridge Advisors first reported a position in Translational Development Acquisition Corp Warrants in Q1 2025 and held it in 1 quarter.
  • Crossingbridge Advisors's Translational Development Acquisition Corp Warrants position peaked at $257K in Q1 2025.
  • 28 funds tracked by Wall St. Rank held Translational Development Acquisition Corp Warrants as of Q2 2025.

Based on Crossingbridge Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.